Blair William & Co. IL Raises Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Key Points

• Blair William & Co. IL increased its holdings in Recursion Pharmaceuticals by 854.2% in Q1, now owning 114,500 shares valued at $606,000.
• Recursion Pharmaceuticals reported a loss of $0.41 per share for the last quarter, missing consensus estimates, but had a 33.3% increase in revenue compared to the previous year.
• Analysts rate Recursion Pharmaceuticals with an average rating of "Hold" and a target price of around $7.00, with research from Needham maintaining a "buy" rating and an $8.00 target.

Blair William & Co. IL raised its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 854.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 114,500 shares of the company's stock after acquiring an additional 102,500 shares during the quarter. Blair William & Co. IL's holdings in Recursion Pharmaceuticals were worth $606,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Softbank Group CORP. acquired a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth approximately $99,152,000. Novo Holdings A S acquired a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth approximately $68,375,000. ARK Investment Management LLC raised its stake in shares of Recursion Pharmaceuticals by 7.6% during the 1st quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company's stock worth $184,174,000 after buying an additional 2,469,104 shares during the period. Laurion Capital Management LP acquired a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth approximately $16,611,000. Finally, Kinnevik AB publ raised its stake in shares of Recursion Pharmaceuticals by 12.8% during the 1st quarter. Kinnevik AB publ now owns 13,434,171 shares of the company's stock worth $71,067,000 after buying an additional 1,528,503 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Price Performance

NASDAQ RXRX traded up $0.15 during mid-day trading on Friday, hitting $5.79. The stock had a trading volume of 3,336,852 shares, compared to its average volume of 24,892,203. The firm's 50 day moving average is $5.48 and its 200 day moving average is $5.86. Recursion Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $12.36. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 3.58. The stock has a market capitalization of $2.35 billion, a price-to-earnings ratio of -3.25 and a beta of 0.93.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The firm had revenue of $19.10 million during the quarter, compared to analyst estimates of $15.38 million. During the same period in the prior year, the company posted ($0.40) earnings per share. The firm's revenue for the quarter was up 33.3% compared to the same quarter last year. Equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on RXRX. Needham & Company LLC reaffirmed a "buy" rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Tuesday, July 8th. Morgan Stanley assumed coverage on Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 target price for the company. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, Recursion Pharmaceuticals has an average rating of "Hold" and a consensus price target of $7.00.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.